382 related articles for article (PubMed ID: 32497971)
1. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
Post CCB; Westermann AM; Bosse T; Creutzberg CL; Kroep JR
Crit Rev Oncol Hematol; 2020 Aug; 152():102973. PubMed ID: 32497971
[TBL] [Abstract][Full Text] [Related]
2. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors and immunotherapy in ovarian and endometrial cancers.
Miller RE; Lewis AJ; Powell ME
Br J Radiol; 2021 Dec; 94(1128):20210002. PubMed ID: 33882241
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.
Lee EK; Konstantinopoulos PA
Trends Cancer; 2019 Sep; 5(9):524-528. PubMed ID: 31474356
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Development of PARP and Immune-Checkpoint Inhibitor Combinations.
Stewart RA; Pilié PG; Yap TA
Cancer Res; 2018 Dec; 78(24):6717-6725. PubMed ID: 30498083
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
9. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
12. Prospects for combining immune checkpoint blockade with PARP inhibition.
Li A; Yi M; Qin S; Chu Q; Luo S; Wu K
J Hematol Oncol; 2019 Sep; 12(1):98. PubMed ID: 31521196
[TBL] [Abstract][Full Text] [Related]
13. Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer.
Shen K; Yang L; Li FY; Zhang F; Ding LL; Yang J; Lu J; Wang NN; Wang Y
Curr Drug Targets; 2022; 23(2):145-155. PubMed ID: 34139979
[TBL] [Abstract][Full Text] [Related]
14. New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?
Rodriguez-Freixinos V; Karakasis K; Oza AM
Curr Oncol Rep; 2016 Apr; 18(4):23. PubMed ID: 26922329
[TBL] [Abstract][Full Text] [Related]
15. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
Xue C; Xu Y; Ye W; Xie Q; Gao H; Xu B; Zhang D; Jiang J
Gynecol Oncol; 2020 Apr; 157(1):222-233. PubMed ID: 31987601
[TBL] [Abstract][Full Text] [Related]
16. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and targeted therapy combinations in metastatic breast cancer.
Esteva FJ; Hubbard-Lucey VM; Tang J; Pusztai L
Lancet Oncol; 2019 Mar; 20(3):e175-e186. PubMed ID: 30842061
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance.
Mamat Yusof MN; Chew KT; Kampan NC; Shafiee MN
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894913
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
